Patrick M Sweeney & Associates Inc. Reduces Stake in Haleon plc (NYSE:HLN)

Patrick M Sweeney & Associates Inc. reduced its position in Haleon plc (NYSE:HLN) by 27.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 70,043 shares of the company’s stock after selling 26,500 shares during the period. Patrick M Sweeney & Associates Inc.’s holdings in Haleon were worth $668,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Fortitude Family Office LLC purchased a new position in shares of Haleon in the 3rd quarter worth $28,000. Versant Capital Management Inc boosted its stake in shares of Haleon by 2,029.1% in the 4th quarter. Versant Capital Management Inc now owns 3,513 shares of the company’s stock worth $34,000 after buying an additional 3,348 shares during the last quarter. Geneos Wealth Management Inc. purchased a new position in shares of Haleon in the 4th quarter worth $35,000. Toronto Dominion Bank boosted its stake in shares of Haleon by 3,470.0% in the 3rd quarter. Toronto Dominion Bank now owns 3,570 shares of the company’s stock worth $38,000 after buying an additional 3,470 shares during the last quarter. Finally, Prospera Private Wealth LLC purchased a new position in shares of Haleon in the 3rd quarter worth $57,000. 6.67% of the stock is currently owned by hedge funds and other institutional investors.

Haleon Price Performance

NYSE:HLN opened at $9.59 on Tuesday. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. The business’s 50-day simple moving average is $9.54 and its two-hundred day simple moving average is $9.74. The stock has a market cap of $43.39 billion, a PE ratio of 28.19, a P/E/G ratio of 2.60 and a beta of 0.29. Haleon plc has a 52 week low of $7.89 and a 52 week high of $10.80.

Haleon (NYSE:HLN) last posted its quarterly earnings results on Thursday, October 31st. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.03. The business had revenue of $3.62 billion for the quarter, compared to analysts’ expectations of $3.74 billion. Haleon had a return on equity of 14.76% and a net margin of 10.85%. During the same period last year, the firm earned $0.10 earnings per share. As a group, analysts forecast that Haleon plc will post 0.44 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

HLN has been the topic of several analyst reports. UBS Group upgraded Haleon to a “strong-buy” rating in a research report on Tuesday, October 1st. Sanford C. Bernstein downgraded Haleon from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 8th. Finally, Morgan Stanley downgraded Haleon from an “overweight” rating to an “equal weight” rating in a research report on Friday, January 10th. Three research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Haleon has a consensus rating of “Moderate Buy” and a consensus price target of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.